Connect with us

Technology

Venturi Cardiology and Caristo Diagnostics Introduce AI-Enabled Heart Disease Diagnosis and Prevention Technology in North West England

Published

1 day ago

on

 

 

OXFORD, England, Sept. 18, 2024 /PRNewswire/ — Venturi Cardiology, a leading, state of the art cardiology clinic in North West England offering rapid access to clinical consultations and advanced diagnostics, has partnered with Caristo Diagnostics, a global leader in cardiovascular disease diagnostics and risk prediction, to offer Caristo’s AI-enabled CaRi-Heart® technology to patients in its growing practice. Venturi Cardiology is part of DHC Group, a portfolio of healthcare companies that supply specialist outpatient pathways and diagnostic imaging services. 

CaRi-Heart technology applies advanced AI algorithms to routine coronary computed tomography angiography (CCTA) scans to visualise and quantify coronary inflammation, the otherwise invisible disease mechanism responsible for many fatal heart attacks. Venturi Cardiology are initially offering an Incentivised Test package for patients requesting CaRi-Heart analysis as part of their CCTA (Coronary Computed Tomography Angiography) scan. Further details can be found on their website: www.venturicardiology.com/cari-heart-analysis.

“At Venturi, our approach to cardiac care is preventative and personalised for each patient. We are excited to offer the CaRi-Heart AI technology, which reveals an individual’s risk of heart attack over the next 8-10 years. This groundbreaking technology can revolutionise early detection and prevention of coronary artery disease,” said Dr Scott Murray, Consultant Cardiologist and Medical Director at Venturi Cardiology.

“Coronary artery disease is the world’s No. 1 killer, but its impact could be dramatically reduced if physicians were able to spot coronary inflammation before a patient suffers from a fatal or non-fatal cardiac event. We are delighted to partner with Venturi Cardiology and DHC Group to bring this life-saving technology to their patients. This partnership will allow increased patient access to the innovative CaRi-Heart technology and can transform the management and treatment of coronary artery disease,” said Frank Cheng, CEO, Caristo Diagnostics.

As confirmed in a recent peer-reviewed study in The Lancet, CaRi-Heart’s unique biomarker, the FAI-Score™, detects invisible coronary inflammation and assesses an individual’s risk of a fatal cardiac event. This is potentially lifesaving for patients who, despite a negative CCTA result, remain at high risk for cardiovascular events. Addressing this residual risk is a significant unmet need in cardiac care.

The landmark Lancet study conducted by researchers at the University of Oxford and other UK clinical institutions analysed results from 40,000 patients’ CCTAs, finding that:

About 80% of patients did not have obstructive coronary artery disease at the time of imaging, but twice as many fatal and non-fatal cardiac events occurred in that groupCoronary inflammation, as measured by Caristo’s CaRi-Heart FAI-Score, predicted fatal and non-fatal cardiac events (including heart attack and new heart failure), independently from traditional risk factors, routine clinical CCTA interpretation, calcium scoring and plaque quantification, at least 10 years in advanceThe CaRi-Heart Risk Score outperformed other scores in routine clinical use for prediction of cardiac mortality, and when presented to clinicians, resulted in changes of management in 45% of the patients.

CaRi-Heart technology is currently in clinical use across the UK, European Union, and Australia.

About Venturi Cardiology

Venturi Cardiology provides independent cardiology clinics, offering rapid access to clinical consultations and advanced diagnostic investigations. Using the latest technology, they provide patients in the North West and those further afield, with easy access to the very best cardiovascular care.

Venturi’s clinical practice is led by a group of dedicated cardiologists that offer exceptional credentials and more than 30 years of combined expertise in preventative cardiology, cardiac imaging and invasive cardiology. They combine independent Cardiology practice with ongoing work for the NHS, to provide an integrated new ‘hybrid’ approach. By merging preventative and clinical Cardiology with a transparent, accessible system, it helps patients feel completely at ease at every stage of their care. Venturi Cardiology is part of the DHC Group of companies.

About DHC Group

DHC Group is a portfolio of healthcare companies based in the United Kingdom. Our companies are all connected by a common purpose – to supply specialist outpatient pathways and diagnostic imaging services. With over 20 years of experience and a national footprint, DHC Group delivers market-leading services tailored to clients’ needs across the public and private healthcare sectors. Our areas of expertise include Radiology (mobile / relocatable, CDCs and static sites), Cardiology and Dental imaging.

About Caristo Diagnostics

Caristo Diagnostics is a global leader in cardiac and vascular disease diagnostics and risk prediction. Founded in 2018 as a spin-out company from the University of Oxford, the world’s #1 research university, Caristo has developed a portfolio of imaging-based and AI-assisted platforms that can be applied to aid the prediction and diagnosis of heart attack, stroke, and diabetes. Caristo has been recognized by Newsweek as one of the best digital health companies, and highlighted by Nature as one of the most exciting science-based companies to have emerged from academic labs. Find Caristo online on its website, LinkedIn and X.

 

Logo: https://mma.prnewswire.com/media/2054669/Caristo.jpg
Logo: https://mma.prnewswire.com/media/2508508/4918452/Venturi.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/venturi-cardiology-and-caristo-diagnostics-introduce-ai-enabled-heart-disease-diagnosis-and-prevention-technology-in-north-west-england-302251761.html

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Dana-Farber Cancer Institute Partners with Clinical.ly to Enhance Regulatory Operations with eReg Solutions

Published

14 mins ago

on

September 19, 2024

By

NEW YORK, Sept. 19, 2024 /PRNewswire/ — The Dana-Farber Cancer Institute, a world leader in cancer treatment and research, chose Clinical.ly’s (www.clinical.ly) Research Suite™ to streamline regulatory operations, marking a significant step toward more efficient and compliant clinical trial management. Dana-Farber joins a growing number of research organizations that leverage Clinical.ly’s innovative solutions to streamline clinical trial processes. Clinical.ly’s eReg platform offers a comprehensive, paperless solution that centralizes regulatory workflows, ensuring compliance and transparency across clinical trials.

“We are thrilled to support Dana-Farber’s clinical research operations,” said Henry Kravchenko, Clinical.ly’s CEO.

This partnership continues Clinical.ly’s success in providing best-in-class enterprise tools for conducting clinical research. “We are thrilled to support Dana-Farber’s clinical research operations,” said Henry Kravchenko, Clinical.ly’s CEO. “Our eReg platform and wider set of features in Clinical.ly Research Suite™ will empower that renowned organization, and we all look forward to supporting their teams.”

About Clinical.ly Research Suite™ 

Clinical.ly Research Suite™ is a comprehensive solution that eliminates traditional, paper-based processes. By automating and centralizing essential workflows in the Clinical.ly Research Suite™, organizations achieve huge efficiency improvements, greater trial oversight, document management, and regulatory compliance. The Clinical.ly Research Suite™ includes:

eReg: A best-in-class electronic regulatory bindereSource: An intuitive & feature-rich, paperless data capture solution that streamlines data collection from trial participantseConsent: A fully digital solution for capturing informed consent, improving participant engagement and site complianceClinicallySign: 21 CFR Part 11 compliant eSignature functionalityClinicallyPay: A secure and instantaneous participant stipend payment and reimbursement solution

About Dana-Farber Cancer Institute

Founded in 1947, Dana-Farber Cancer Institute is committed to providing adults and children with the best treatment available today while developing tomorrow’s cures through cutting-edge research. Based in Boston, Dana-Farber is a teaching affiliate of Harvard Medical School and ranks consistently as one of the top cancer hospitals in the world.

About Clinical.ly

Clinical.ly provides differentiated, cloud-native technology solutions to the clinical research industry, enabling research organizations to conduct studies with greater efficiency and ease. Clinical.ly is dedicated to developing technology that eliminates tedious manual labor, allowing clinical research professionals to focus on patient care.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dana-farber-cancer-institute-partners-with-clinically-to-enhance-regulatory-operations-with-ereg-solutions-302253690.html

SOURCE Clinical.ly

Continue Reading

Technology

Fall Into Creativity with the Monport Laser Fall Sale

Published

14 mins ago

on

September 19, 2024

By

NEW YORK, Sept. 19, 2024 /PRNewswire/ — Experience laser innovation this Fall with Monport Laser, an industry frontrunner in laser engraving and cutting technology, with an exclusive Fall Sale offering incredible discounts and free accessories on a wide range of high-performance laser engraving machines. From September 19th to September 30th, customers can take advantage of this limited-time opportunity to elevate their laser engraving businesses with cutting-edge laser innovation at unbeatable prices.

Monport Laser has been dedicated to providing innovative and reliable laser machines that empower businesses and individuals to achieve their goals. With a focus on quality, precision, and customer satisfaction, Monport Laser has established itself as a trusted leader in the industry. Their commitment to excellence is evident in every laser they produce, ensuring exceptional performance, reliability, and value.

Embrace the Power of CO2 Laser Technology with Exclusive Offers

Monport Laser will offer two free accessories with selected CO2 laser machines during the Monport Fall sale. These versatile lasers are ideal for various applications, including engraving, cutting, and marking wood, acrylic, leather, and more. By taking advantage of this Fall sale, laser engraving businesses can enhance their productivity and expand their creative possibilities.

Experience Unmatched Value with Fiber Laser Discounts

Monport Laser offers substantial discounts of up to $4200 and 3 free accessories on selected models for those seeking the precision and speed of fiber laser technology. Fiber lasers are renowned for their ability to process metals with exceptional efficiency and accuracy, making them indispensable for metal fabrication, manufacturing, and jewelry production. Additionally, customers purchasing fiber lasers during the Fall sale will receive three free accessories, further sweetening the deal.

Elevate Your Desktop Laser Experience with a Free Water Chiller

Monport Laser is committed to providing comprehensive solutions for businesses of all sizes. As part of the Fall sale, customers who purchase the 40W Desktop laser will receive a Free Water Chiller Cw3000. This essential accessory ensures optimal cooling and performance, prolonging the lifespan of the laser and guaranteeing consistent results.

Discover Additional Savings on a Wide Range of Accessories

Monport Laser offers an additional 20% discount on selected accessories to complete your laser setup. From lenses and nozzles to rotary tables and smoke extraction systems, customers can find everything they need to maximize the potential of their laser machines.

Unleash Your Creativity and Productivity

Monport Laser’s Fall sale is the perfect opportunity to invest in laser technology that empowers your business or fuels your creative passions. With exceptional discounts and free accessories, you can acquire the ideal laser solution to meet your needs and budget.

Whether you’re an entrepreneur, artist, or manufacturer, Monport Laser’s advanced laser machines offer unparalleled precision, versatility, and reliability. Take advantage of this limited-time Fall sale and unlock your projects’ full potential for laser innovation.

About Monport Laser

Monport Laser is a global leader in designing, manufacturing, and distributing high-quality laser machines and accessories. With a commitment to innovation and customer satisfaction, Monport Laser provides cutting-edge solutions for various industries, including manufacturing, engraving, marking, and more.

For more information, visit monportlaser.com and follow them on social media for the latest updates.

Website: https://www.monportlaser.com/

 

 

 

View original content:https://www.prnewswire.com/news-releases/fall-into-creativity-with-the-monport-laser-fall-sale-302253699.html

SOURCE Monport Laser

Continue Reading

Technology

MEDIA ADVISORY – Minister Wilkinson to Make a Critical Minerals Infrastructure Announcement

Published

14 mins ago

on

September 19, 2024

By

VANCOUVER, BC, Sept. 19, 2024 /CNW/ – The Honourable Jonathan Wilkinson, Minister of Energy and Natural Resources, and Ranj Pillai, the Premier of Yukon, will make a funding announcement in support of critical minerals infrastructure projects. A media availability will follow.

Date: September 20, 2024

Time: 10:30 a.m. PT

All accredited media are asked to pre-register by emailing media@nrcan-rncan.gc.ca. A dial-in line is available for media and will be provided upon registration.

Follow us on LinkedIn

SOURCE Natural Resources Canada

Continue Reading

Trending